^
Association details:
| Biomarker: | PTEN mutation |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | taselisib (GDC-0032) (PIK3CA inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Taselisib (GDC-0032), a Potent ß-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations
Excerpt:
Additionally, we found that PTEN aberrations were associated with resistance to GDC-0032, with 4 of the 6 most resistant HSNCC cell lines to this agent containing PTEN alterations, also consistent with previous data from our group
DOI:
10.1158/1078-0432.CCR-15-2245
